Typhoid Conjugate Vaccine for Prevention of Typhoid Fever: A Systematic Review of Randomized Controlled Trials with Relevance to Travel Medicine

Authors

  • Zaki Mahmudi Dasril Universitas Prima Nusantara Bukittinggi Author
  • Febrita Joniarti Universitas Prima Nusantara Bukittinggi Author

DOI:

https://doi.org/10.35730/z04msz05

Keywords:

Typhoid fever, typhoid conjugate vaccine, travel medicine, randomized controlled trial

Abstract

Background: Typhoid fever is a vaccine-preventable infection of importance to residents of endemic areas and to travelers to South Asia and Africa. Typhoid conjugate vaccines (TCVs) have been evaluated in field randomized controlled trials (RCTs). This systematic review summarizes their efficacy and safety.

Methods: RCTs of Vi-conjugate typhoid vaccines in children, using a non-typhoid control vaccine and reporting blood-culture-confirmed typhoid fever, were eligible. Data were extracted and synthesized without meta-analysis following the SWiM reporting guideline, with qualitative risk-of-bias appraisal using RoB 2 domains.

Findings: Three RCTs (Nepal, Malawi, Bangladesh; more than 100,000 vaccinated or randomized children) were included. Vaccine efficacy against blood-culture-confirmed typhoid fever was 81.6% (95% CI 58.8–91.8) in Nepal, 80.7% (95% CI 64.2–89.6) in Malawi, and 85% (97.5% CI 76–91) total protection in Bangladesh. Serious adverse events were balanced between groups, and none were attributed to the vaccine in Malawi and Bangladesh; one vaccine-related event (pyrexia) was reported in Nepal.

Conclusion: TCV showed high efficacy and an acceptable safety profile in children in endemic settings. Direct evidence for adult travelers was not found in the trials reviewed.

Downloads

Published

2026-09-30